Arcutis Biotherapeutics (ARQT) Institutional Ownership
13F filers reported holding 19.0% of Arcutis Biotherapeutics (ARQT) shares as of Sep 30, 2026, across 144 filers.
- Held by 13F filers
- 19.0%
- Sep 30, 2026
- 13F filers
- 144
- quarter ended Sep 30, 2026
- 13F value
- $634.1M
- 24.0M shares
- Quarter's fund flow
- Mild accumulation
- 40 new · 11 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | Matsuda Masaru | EVP, Chief Legal Officer | Acquired · Option exercise | 40,000 | $3.64 | ↗ |
| Nov 4, 2026 | Matsuda Masaru | EVP, Chief Legal Officer | Disposed · Open-market sale | 40,000 | $34.32 | ↗ |
| Nov 4, 2026 | Matsuda Masaru | EVP, Chief Legal Officer | Disposed · Option exercise | 40,000Stock Option (right to buy) | — | ↗ |
| Nov 2, 2026 | Matsuda Masaru | EVP, Chief Legal Officer | Disposed · Open-market sale | 1,219 | $31.86 | ↗ |
| Nov 2, 2026 | Burnett Patrick | EVP, Chief Medical Officer | Disposed · Open-market sale | 943 | $31.86 | ↗ |
| Nov 2, 2026 | Watanabe Todd Franklin | See Remarks | Disposed · Open-market sale | 4,377 | $31.86 | ↗ |
| Oct 23, 2026 | SCOTT ROBERT A | director | Acquired · Grant / award | 2,819 | — | ↗ |
| Oct 23, 2026 | SCOTT ROBERT A | director | Acquired · Grant / award | 20,507Stock Option (right to buy) | — | ↗ |
| Oct 23, 2026 | SCOTT ROBERT A | director | Acquired · Grant / award | 8,663Stock Option (right to buy) | — | ↗ |
| Oct 15, 2026 | Welgus Howard G. | director | Acquired · Option exercise | 822 | $6.52 | ↗ |
| Oct 15, 2026 | Welgus Howard G. | director | Acquired · Option exercise | 1,018 | $7.51 | ↗ |
| Oct 15, 2026 | Welgus Howard G. | director | Acquired · Option exercise | 2,254 | $8.63 | ↗ |
| Oct 15, 2026 | Welgus Howard G. | director | Disposed · Open-market sale | 4,728 | $26.93 | ↗ |
| Oct 15, 2026 | Welgus Howard G. | director | Disposed · Option exercise | 822Stock Option (right to buy) | — | ↗ |
| Oct 15, 2026 | Welgus Howard G. | director | Disposed · Option exercise | 1,018Stock Option (right to buy) | — | ↗ |
| Oct 15, 2026 | Welgus Howard G. | director | Disposed · Option exercise | 2,254Stock Option (right to buy) | — | ↗ |
| Sep 16, 2026 | Matsuda Masaru | See Remarks | Disposed · Open-market sale | 3,674 | $25.00 | ↗ |
| Sep 15, 2026 | Welgus Howard G. | director | Acquired · Option exercise | 822 | $6.52 | ↗ |
| Sep 15, 2026 | Welgus Howard G. | director | Acquired · Option exercise | 1,019 | $7.51 | ↗ |
| Sep 15, 2026 | Welgus Howard G. | director | Acquired · Option exercise | 2,255 | $8.63 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Arcutis Biotherapeutics do institutions hold?
13F filers reported holding 19.0% of Arcutis Biotherapeutics' shares as of Sep 30, 2026, across 144 filers.
How many 13F filers hold Arcutis Biotherapeutics?
Arcutis Biotherapeutics was held by 144 13F filers as of Sep 30, 2026.
Not investment advice.

